We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI Diagnostic Tool Could Deliver Results in Two Minutes Using Fingertip Sample

By LabMedica International staff writers
Posted on 21 Oct 2022

Biofluids such as synovial fluid, blood plasma, and saliva contain proteins that are an important biomarker for the diagnosis of several health conditions. More...

Now, a specially designed platform has been programmed to detect the concentration of these proteins to assist in diagnosis and monitoring disease progression. The research proposes that hospital waiting times could be drastically cut and the option for self-screening and self-monitoring is now possible with the potential for at-home diagnostic kits in the future.

Scientists at Swansea University (Swansea, UK) developing a platform that would use artificial intelligence (AI) to speed up the process of detecting biomarkers in biofluids have shown that the concept could work. It would mean faster test results for health conditions such as cardiovascular disorders, joint quality, and Alzheimer’s disease. The new diagnostic tool could revolutionize the healthcare sector due to the application of a form of AI – machine learning (ML). The implementation of ML has meant it is possible, for the first time, for results to be delivered within minutes.

“The key innovation is the fact of providing a result within two minutes, which is a leap forward compared to standard testing that can take several hours,” said Dr. Francesco Del Giudice, project lead. "What this means for the future is that our proof-of-concept study can be further developed in a tool to help clinicians making decisions on clinical data obtained quickly. We also foresee to develop this further for an at-home-point-of-care self-screening diagnostic platform.”

“The ability of artificial intelligence to drive down the time required to complete various tasks has been demonstrated across a number of disciplines,” added Dr. Claire Barnes, co-author on the work. “The advantage of speed offered by the implementation of machine learning allowed us to adjust almost in real-time the experimental parameters to fulfill the requirements of the theoretical model associated with this work.”

Related Links:
Swansea University 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.